These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28703785)

  • 1. Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside.
    Pawlowski M; Meuth SG; Duning T
    Diagnostics (Basel); 2017 Jul; 7(3):. PubMed ID: 28703785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.
    Bjerke M; Engelborghs S
    J Alzheimers Dis; 2018; 62(3):1199-1209. PubMed ID: 29562530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
    Toledo JB; Zetterberg H; van Harten AC; Glodzik L; Martinez-Lage P; Bocchio-Chiavetto L; Rami L; Hansson O; Sperling R; Engelborghs S; Osorio RS; Vanderstichele H; Vandijck M; Hampel H; Teipl S; Moghekar A; Albert M; Hu WT; Monge Argilés JA; Gorostidi A; Teunissen CE; De Deyn PP; Hyman BT; Molinuevo JL; Frisoni GB; Linazasoro G; de Leon MJ; van der Flier WM; Scheltens P; Blennow K; Shaw LM; Trojanowski JQ;
    Brain; 2015 Sep; 138(Pt 9):2701-15. PubMed ID: 26220940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
    Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
    Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments.
    Zetterberg H
    Curr Opin Psychiatry; 2015 Sep; 28(5):402-9. PubMed ID: 26147615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.
    Blennow K; Biscetti L; Eusebi P; Parnetti L
    Mov Disord; 2016 Jun; 31(6):836-47. PubMed ID: 27145480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.
    Somers C; Goossens J; Engelborghs S; Bjerke M
    Biomark Med; 2017 Feb; 11(2):169-178. PubMed ID: 28111962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer's Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients.
    Tsantzali I; Boufidou F; Sideri E; Mavromatos A; Papaioannou MG; Foska A; Tollos I; Paraskevas SG; Bonakis A; Voumvourakis KI; Tsivgoulis G; Kapaki E; Paraskevas GP
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics.
    Ritter A; Cummings J
    Front Neurol; 2015; 6():186. PubMed ID: 26379620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression.
    Begcevic I; Tsolaki M; Brinc D; Brown M; Martinez-Morillo E; Lazarou I; Kozori M; Tagaraki F; Nenopoulou S; Gkioka M; Lazarou E; Lim B; Batruch I; Diamandis EP
    F1000Res; 2018; 7():1012. PubMed ID: 30191060
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.